Consensus Stoke Therapeutics, Inc.

Equities

STOK

US86150R1077

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
12.41 ^USD	+6.16%		+2.99%	+135.93%

17/04	Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer	CI
28/03	Sector Update: Health Care Stocks Advance Premarket Thursday	MT

Evolution of the average Target Price on Stoke Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

41077561269b0faa0f57d.VOKnCRU2GwqiXAaC96llajHOfDzO-qwZ8xe2Jyb92pI.Mqjwc3oEYUX2K0zYhZESW0SLPQ6mqJwgkC_Af1eojqsCifF7YAd9YcAPNg~44259f86db1653a4c6fc35ed7c6d3a73

Analyst Recommendations on Stoke Therapeutics, Inc.

JPMorgan Adjusts Price Target on Stoke Therapeutics to $13 From $6, Maintains Neutral Rating	26/03	MT
Needham Adjusts Stoke Therapeutics' Price Target to $22 From $14, Maintains Buy Rating	26/03	MT
Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $21 From $18, Keeps Buy Rating	26/03	MT
Wedbush Adjusts Stoke Therapeutics' Price Target to $17 From $13, Keeps Outperform Rating	26/03	MT
Canaccord Genuity Adjusts Stoke Therapeutics Price Target to $21 From $18, Maintains Buy Rating	26/03	MT
TD Cowen Upgrades Stoke Therapeutics to Outperform From Market Perform	26/03	MT
Wedbush Lowers Stoke Therapeutics' Price Target to $13 From $18, Shifts STK-001 Launch Timing; Retains Outperform Rating	08/23/08	MT
Wedbush Adjusts Stoke Therapeutics Price Target to $18 From $22, Maintains Outperform Rating	25/23/25	MT
Cantor Fitzgerald Adjusts Price Target on Stoke Therapeutics to $25 From $20, Keeps Overweight Rating	23/23/23	MT
Wedbush Lowers Stoke Therapeutics' Price Target to $22 From $25 on Higher Share Count, Keeps Outperform Rating	05/23/05	MT
BofA Securities Upgrades Stoke Therapeutics to Neutral From Underperform, Adjusts Price Target to $12 From $9	01/23/01	MT
Canaccord Genuity Assumes Stoke Therapeutics at Buy With $24 Price Target	26/23/26	MT
Credit Suisse Lowers Stoke Therapeutics' Price Target to $28 From $32, Updates Model to Reflect Q4 Actuals; Keeps Outperform Rating	07/23/07	MT
Wedbush Lowers Stoke Therapeutics' Price Target to $25 From $33, Pushes Out STK-001 Launch Timing By 1 Year; Keeps Outperform Rating	07/23/07	MT
Credit Suisse Lowers Stoke Therapeutics' Price Target to $32 From $38, Keeps Outperform Rating	11/23/11	MT
HC Wainwright Adjusts Stoke Therapeutics' Price Target to $35 From $70, Keeps Buy Rating	05/22/05	MT
Credit Suisse Lowers Stoke Therapeutics' Price Target to $38 From $50, Keeps Outperform Rating	15/22/15	MT
Credit Suisse Lowers Stoke Therapeutics' Price Target to $50 from $54, Maintains Outperform Rating	09/22/09	MT
Cantor Fitzgerald Adjusts Price Target for Stoke Therapeutics to $38 From $68, Retains Overweight Rating	26/22/26	MT
Credit Suisse Lowers Stoke Therapeutics' Price Target to $54 from $58, Keeps Outperform Rating	11/22/11	MT
Wedbush Adjusts Price Target for Stoke Therapeutics to $33 From $32, Maintains Outperform Rating	11/22/11	MT
BofA Securities Adjusts Stoke Therapeutics' Price Target to $40 from $43, Keeps Buy Rating	16/22/16	MT
Wedbush Adjusts Stoke Therapeutics' Price Target to $32 From $48; Outperform Rating Kept	10/22/10	MT
Jefferies & Co Initiates Coverage on Stoke Therapeutics With Buy Rating, $50 Price Target	31/22/31	MT
BofA Securities Starts Stoke Therapeutics at Buy With $43 Price Target	03/21/03	MT